Related Experiment Video
Updated: May 1, 2026
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
From mice to men: GEMMs as trial patients for new NSCLC therapies
Sarah A Hayes1, Amanda L Hudson1, Stephen J Clarke1
1Bill Walsh Translational Cancer Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St. Leonards, New South Wales, Australia; Department of Medical Oncology, Royal North Shore Hospital, University of Sydney, St. Leonards, New South Wales, Australia.
Abstract:
Given the large socio-economic burden of cancer, there is an urgent need for in vivo animal cancer models that can provide a rationale for personalised therapeutic regimens that are translatable to the clinic. Recent developments in establishing mouse models that closely resemble human lung cancers involve the application of genetically engineered mouse models (GEMMs) for use in drug efficacy studies or to guide patient therapy. Here, we review recent applications of GEMMs in non-small cell lung cancer research for drug development and their potential in aiding biomarker discovery and understanding of biological mechanisms behind clinical outcomes and drug interactions.
Insights
Genetically engineered mouse models (GEMMs) are crucial for advancing lung cancer research. These models aid in developing personalized therapies and understanding treatment responses in non-small cell lung cancer.
Area of Science:
- Oncology
- Genetics
- Translational Medicine
Background:
- Cancer imposes a significant socio-economic burden, necessitating effective in vivo models for personalized treatment strategies.
- Genetically engineered mouse models (GEMMs) are increasingly vital for preclinical research, closely mimicking human lung cancers.
- The development of reliable animal models is essential for translating therapeutic findings from bench to bedside.
Purpose of the Study:
- To review the recent applications of GEMMs in non-small cell lung cancer (NSCLC) research.
- To highlight the utility of GEMMs in drug development and efficacy studies.
- To explore the potential of GEMMs in biomarker discovery and understanding treatment mechanisms.
Main Methods:
- Literature review focusing on studies utilizing GEMMs in NSCLC research.
- Analysis of GEMM applications in drug efficacy testing.
- Examination of GEMM contributions to biomarker identification and mechanistic studies.
Main Results:
- GEMMs are instrumental in advancing drug development for NSCLC.
- These models facilitate the discovery of potential biomarkers for targeted therapies.
- GEMMs provide insights into the biological mechanisms underlying clinical outcomes and drug interactions.
Conclusions:
- GEMMs represent a powerful tool for personalized therapeutic regimen development in NSCLC.
- Their application accelerates drug discovery and enhances the understanding of treatment responses.
- GEMMs are essential for bridging the gap between preclinical research and clinical application in lung cancer therapy.
